177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer (NCT04663997)
🩺 Plain-English Summary (8th-Grade Level)
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (12 items).
Location: Tom Baker Cancer Centre — Calgary, Alberta
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior treatment with chemotherapy for castration-resistant disease or prior chemotherapy in the castration-sensitive (hormone-sensitive) setting ≤ 1 year prior to enrollment.
- Prior treatment with 177Lu-PSMA (including other radiolabeled therapeutic PSMA-ligands) or radio-immunotherapy. Prior treatment with radium-223 is allowed but requires a minimum of a 6-month interval between the last dose of radium-223 and enrollment.
- Radiotherapy to target lesions (measurable disease) ≤ 12 weeks prior to enrolment.
- Presence of majority (\> 50% of extra-osseous lesions) or large (\> 5 cm) soft tissue lesions that are negative on PSMA-Ligand PET/CT or PSMA-Ligand PET/MR
- Known parenchymal brain metastases
- Active epidural disease (treated epidural disease is permitted)
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Clinically significant cardiac disease
- Major surgery within 4 weeks of starting study treatment
- Patients with a history of hypersensitivity to the study drug or components
- Patients with a clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or sever psychiatric illness/social situations.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (10 Sites)
- Tom Baker Cancer Centre — Calgary, Alberta
- Cross Cancer Institute — Edmonton, Alberta
- BCCA - Vancouver Cancer Centre — Vancouver, British Columbia
- London Regional Cancer Program — London, Ontario
- Odette Cancer Centre — Toronto, Ontario
- University Health Network — Toronto, Ontario
- CHUM-Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec
- The Jewish General Hospital — Montreal, Quebec
- Hotel-Dieu de Quebec — Québec, Quebec
- CIUSSS de l'Estrie - Centre hospitalier — Sherbrooke, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.